Please provide your email address to receive an email when new articles are posted on . The study, comparing the 1% and 2% formulations of the drug, found the 2% topical to be effective. 62.5% of ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

Please provide your email address to receive an email when new articles are posted on . Acne was an adverse event for 6.2% of patients treated with Janus kinase (JAK) inhibitors vs. 1.3% of controls.

The JAK2 gene is a protein-coding gene of the Janus kinase family. It plays a role in cellular signaling. Evidence notes connections between this gene and some medical conditions. Variations in this ...

A panel held at Fall Clinical Dermatology 2023 emphasized the role of Janus kinase (JAK) inhibitors in several skin conditions and highlighted new therapies in the space. Fall Clinical Dermatology ...

JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

A new research perspective titled "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma" has been published in Oncotarget. In this new paper, researchers ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Some previous studies, including the ORAL Surveillance randomized trial, have shown moderately greater cancer risks with JAK inhibitors versus TNF inhibitors. But some other analyses of real-world ...